Using a Precision-Medicine Platform to Address Polypharmacy in Cognitive Impairment
By William Tsun
At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease.
The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source database, and then attend to each in a generated treatment plan.
To read the public release, click here.